{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:11:46Z","timestamp":1791173506813,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004761","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health Research Project of Hunan Provincial Health Commission"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02041-w","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:16:05Z","timestamp":1772064965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in the role of long non-coding RNAs in ovarian cancer chemoresistance"],"prefix":"10.1186","volume":"19","author":[{"given":"Shanshan","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2041_CR1","doi-asserted-by":"publisher","first-page":"643129","DOI":"10.3389\/fonc.2021.643129","volume":"11","author":"F Bi","year":"2021","unstructured":"Bi F, An Y, Sun T, et al. PHGDH is upregulated at translational level and implicated in platin-resistant in ovarian cancer cells [J]. Front Oncol. 2021;11:643129.","journal-title":"Front Oncol"},{"issue":"5","key":"2041_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051299","volume":"9","author":"M Nowak","year":"2020","unstructured":"Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells. 2020;9(5):1299.","journal-title":"Cells"},{"issue":"3","key":"2041_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.3192","volume":"47","author":"MK Iyer","year":"2015","unstructured":"Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47(3):199\u2013208.","journal-title":"Nat Genet"},{"issue":"11","key":"2041_CR4","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/nm.3981","volume":"21","author":"M Huarte","year":"2015","unstructured":"Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253\u201361.","journal-title":"Nat Med"},{"key":"2041_CR5","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.omtn.2021.03.018","volume":"24","author":"B Yadav","year":"2021","unstructured":"Yadav B, Pal S, Rubstov Y, et al. LncRNAs associated with glioblastoma: From transcriptional noise to novel regulators with a promising role in therapeutics[J]. Mol Ther Nucleic Acids. 2021;24:728\u201342.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2041_CR6","doi-asserted-by":"crossref","unstructured":"Kung JTY, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future [J]. Genetics, 201, 193(3): 651\u201369.","DOI":"10.1534\/genetics.112.146704"},{"issue":"2","key":"2041_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0329-5","volume":"32","author":"RB Leng","year":"2015","unstructured":"Leng RB, Liao G, Wang HX, et al. Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome. Med Oncol. 2015;32(2):329.","journal-title":"Med Oncol"},{"issue":"4","key":"2041_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/IGC.0000000000000413","volume":"25","author":"CC Ren","year":"2015","unstructured":"Ren CC, Li XB, Wang TZ, et al. Functions and mechanisms of long noncoding RNAs in ovarian cancer. Int J Gynecol Cancer. 2015;25(4):566\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"2041_CR9","doi-asserted-by":"crossref","unstructured":"De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression [J]. Nat Rev Cancer, 201, 13(2): 97\u2013110.","DOI":"10.1038\/nrc3447"},{"issue":"3","key":"2041_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.4143\/crt.2016.263","volume":"49","author":"GW Yim","year":"2017","unstructured":"Yim GW, Kim HJ, Kim LK, et al. Long non-coding RNA HOXA11 antisense promotes cell proliferation and invasion and predicts patient prognosis in serous ovarian cancer. Cancer Res Treat. 2017;49(3):656\u201368.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"2041_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/19491034.2016.1179408","volume":"7","author":"B Yu","year":"2016","unstructured":"Yu B, Shan G. Functions of long noncoding RNAs in the nucleus. Nucleus. 2016;7(2):155\u201366.","journal-title":"Nucleus"},{"key":"2041_CR12","unstructured":"Bergmann JH, Spector DL. Long non-coding RNAs: modulators of nuclear structure and function [J]. Curr Opin Cell Biol, Morton C. C C. Identification and function of long non-coding RNA [J]. Front Cell Neurosci, 201, 7: 168."},{"key":"2041_CR13","doi-asserted-by":"crossref","unstructured":"Ernst C, Morton CC. Identification and function of long non-coding RNA. Front Cell Neurosci. 201AD;7:168.","DOI":"10.3389\/fncel.2013.00168"},{"issue":"9","key":"2041_CR14","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1002\/cmdc.201300534","volume":"9","author":"A Bhan","year":"2014","unstructured":"Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. ChemMedChem. 2014;9(9):1932\u201356.","journal-title":"ChemMedChem"},{"key":"2041_CR15","doi-asserted-by":"publisher","unstructured":"Ma LN, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 201AD;10(6):925\u20139. https:\/\/doi.org\/10.4161\/rna.24604.","DOI":"10.4161\/rna.24604"},{"issue":"6","key":"2041_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","volume":"43","author":"KC Wang","year":"2011","unstructured":"Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904\u201314.","journal-title":"Mol Cell"},{"key":"2041_CR17","doi-asserted-by":"crossref","unstructured":"Liu TW, Shen JC, He QZ et al. Identification of a novel immune-related lncRNA CTD\u20132288O8.1 regulating cisplatin resistance in ovarian cancer based on integrated analysis [J]. Front Genet, 20, 13: 814291.","DOI":"10.3389\/fgene.2022.814291"},{"issue":"8","key":"2041_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.421","volume":"8","author":"DL Chen","year":"2017","unstructured":"Chen DL, Chen LZ, Lu YX, et al. Long noncoding RNA XIST expedites metastasis and modulates epithelial-mesenchymal transition in colorectal cancer. Cell Death Dis. 2017;8(8):e3011.","journal-title":"Cell Death Dis"},{"issue":"3","key":"2041_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.prp.2018.12.033","volume":"215","author":"YT Chen","year":"2019","unstructured":"Chen YT, Liu L, Li J, et al. Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells [J]. Pathol Res Pract. 2019;215(3):470\u20137.","journal-title":"Pathol Res Pract"},{"issue":"8","key":"2041_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-021-06603-7","volume":"48","author":"JY He","year":"2021","unstructured":"He JY, Zhu SM, Liang X, et al. LncRNA as a multifunctional regulator in cancer multi-drug resistance [J]. Mol Biol Rep. 2021;48(8):1\u201315.","journal-title":"Mol Biol Rep"},{"key":"2041_CR21","doi-asserted-by":"crossref","unstructured":"Zhu YR, Zhou BL, Hu XY et al. LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability [J]. Clin Transl Med, 20, 12(1): e70.","DOI":"10.1002\/ctm2.703"},{"issue":"21","key":"2041_CR22","doi-asserted-by":"publisher","first-page":"24171","DOI":"10.18632\/aging.203672","volume":"13","author":"PP Li","year":"2021","unstructured":"Li PP, Li RG, Huang YQ, et al. LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p\/MTDH pathway-mediated autophagy and genomic instability. Aging Albany NY. 2021;13(21):24171\u201391.","journal-title":"Aging Albany NY"},{"issue":"1","key":"2041_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/nat.2012.0414","volume":"23","author":"Y S\u00e1nchez","year":"2013","unstructured":"S\u00e1nchez Y, Huarte M. Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic Acid Ther. 2013;23(1):15\u201320.","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"2041_CR24","volume":"1878","author":"A Shabna","year":"2023","unstructured":"Shabna A, Bindhya S, Sidhanth C, et al. Long non-coding RNAs: fundamental regulators and emerging targets of cancer stem cells. Biochimica et Biophysica Acta (BBA). 2023;1878(3):188899.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"2041_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.01.032","volume":"519","author":"M Garg","year":"2021","unstructured":"Garg M, Sethi G. Emerging role of long non-coding RNA (lncRNA) in human malignancies: A unique opportunity for precision medicine[J]. Cancer Lett. 2021;519:1.","journal-title":"Cancer Lett"},{"issue":"3","key":"2041_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3390\/cells9030527","volume":"9","author":"S Pal","year":"2020","unstructured":"Pal S, Garg M, Pandey AK. Deciphering the mounting complexity of the p53 regulatory network in correlation to long non-coding RNAs (lncRNAs) in ovarian cancer. Cells. 2020;9(3):527.","journal-title":"Cells"},{"issue":"5","key":"2041_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06704-8","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu J, Yan CS, Xu SH. LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer. Cell Death Dis. 2024;15(5):31.","journal-title":"Cell Death Dis"},{"key":"2041_CR28","doi-asserted-by":"crossref","unstructured":"He SL, Chen YL, Chen QH et al. LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoter [J]. Mol Med, 20, 28(1): 11.","DOI":"10.1186\/s10020-022-00521-5"},{"issue":"1","key":"2041_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1103-5","volume":"38","author":"SS Dong","year":"2019","unstructured":"Dong SS, Wang RR, Wang H, et al. HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res. 2019;38(1):110.","journal-title":"J Exp Clin Cancer Res"},{"key":"2041_CR30","doi-asserted-by":"crossref","unstructured":"Li XD, Zhang Y, Wang XJ et al. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2 [J]. Cell Biol Toxicol, 20, 38(6): 1027\u201345.","DOI":"10.1007\/s10565-021-09650-9"},{"key":"2041_CR31","doi-asserted-by":"crossref","unstructured":"Fan Y, Wang L, Han XC et al. LncRNA ASB16-AS1 accelerates cellular process and chemoresistance of ovarian cancer cells by regulating GOLM1 expression via targeting miR-3918 [J]. Biochem Biophys Res Commun, 20, 675: 1\u20139.","DOI":"10.1016\/j.bbrc.2023.06.068"},{"key":"2041_CR32","doi-asserted-by":"crossref","unstructured":"Shao Y, Li H, Wu Y et al. The feedback loop of AURKA\/DDX5\/TMEM147-AS1\/let-7 drives lipophagy to induce cisplatin resistance in epithelial ovarian cancer [J]. Cancer Lett, 20, 565: 216241.","DOI":"10.1016\/j.canlet.2023.216241"},{"key":"2041_CR33","doi-asserted-by":"crossref","unstructured":"Wu Y, Wang T, Xia L et al. Correction to: LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p\/SDC4 axis [J]. Cancer Cell Int, 20, 23(1): 176.","DOI":"10.1186\/s12935-023-03029-y"},{"issue":"1","key":"2041_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01424-1","volume":"17","author":"X Li","year":"2024","unstructured":"Li X, Zheng Z, Zhou WZ, et al. HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer. J Ovarian Res. 2024;17(1):124.","journal-title":"J Ovarian Res"},{"issue":"1","key":"2041_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71153-0","volume":"10","author":"WX Tan","year":"2020","unstructured":"Tan WX, Sun G, Shangguan MY, et al. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling. Sci Rep. 2020;10(1):14768.","journal-title":"Sci Rep"},{"issue":"6","key":"2041_CR36","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/cas.16150","volume":"115","author":"R Sonobe","year":"2024","unstructured":"Sonobe R, Yang P, Suzuki MM, et al. Long noncoding RNA TUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta [J]. Cancer Sci. 2024;115(6):1910\u201319.","journal-title":"Cancer Sci"},{"key":"2041_CR37","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2147\/CMAR.S295097","volume":"13","author":"XY Jiang","year":"2021","unstructured":"Jiang XY, Cheng Y, He YN, et al. LNC00115 mediates cisplatin resistance by regulating the miR-7\/ERK signalling pathway in ovarian cancer [J]. Cancer Manag Res. 2021;13:3817\u201326.","journal-title":"Cancer Manag Res"},{"key":"2041_CR38","doi-asserted-by":"crossref","unstructured":"Yang HB, Zhang XG, Zhu L et al. YY1-induced lncRNA PART1 enhanced resistance of ovarian cancer cells to cisplatin by regulating miR-512-3p\/CHRAC1 axis [J]. DNA Cell Biol, 2021, 40(6): 821-8.","DOI":"10.1089\/dna.2021.0059"},{"issue":"2","key":"2041_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.yexcr.2018.03.014","volume":"366","author":"L Bai","year":"2018","unstructured":"Bai L, Wang AH, Zhang YL, et al. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res. 2018;366(2):161\u201371.","journal-title":"Exp Cell Res"},{"key":"2041_CR40","doi-asserted-by":"crossref","unstructured":"Zhu Y, Yang LJ, Wang JQ et al. SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1\/IGF2\/MEK\/ERK axis [J]. J Gynecol Oncol, 20, 33(6): e75.","DOI":"10.3802\/jgo.2022.33.e75"},{"issue":"4","key":"2041_CR41","doi-asserted-by":"publisher","first-page":"9829","DOI":"10.1080\/21655979.2022.2061181","volume":"13","author":"CX Lin","year":"2022","unstructured":"Lin CX, Zheng MY, Yang YL, et al. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a. Bioengineered. 2022;13(4):9829\u201338.","journal-title":"Bioengineered"},{"issue":"5","key":"2041_CR42","doi-asserted-by":"publisher","first-page":"13893","DOI":"10.1080\/21655979.2022.2086377","volume":"13","author":"YW Chen","year":"2022","unstructured":"Chen YW, Cui ZL, Wu QL, et al. Long non-coding RNA HOXA11-AS knockout inhibits proliferation and overcomes drug resistance in ovarian cancer [J]. Bioengineered. 2022;13(5):13893\u2013905.","journal-title":"Bioengineered"},{"key":"2041_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtn.2019.05.007","volume":"17","author":"ZW Li","year":"2019","unstructured":"Li ZW, Niu HF, Qin QQ, et al. lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143\/FOSL2-signaling pathway in ovarian cancer. Mol Ther Nucleic Acids. 2019;17:92\u2013101.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"11","key":"2041_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1148-y","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Fang L, Jiang J, et al. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell Death Dis. 2018;9(11):1103.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2041_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1515\/hsz-2017-0274","volume":"399","author":"SW Liu","year":"2018","unstructured":"Liu SW, Lei HJ, Luo FY, et al. The effect of lncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of HOXA7. Biol Chem. 2018;399(5):485\u201397.","journal-title":"Biol Chem"},{"issue":"14","key":"2041_CR46","first-page":"4440","volume":"22","author":"QF Xu","year":"2018","unstructured":"Xu QF, Tang YX, Wang X. LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients. Eur Rev Med Pharmacol Sci. 2018;22(14):4440\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"2041_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13048-024-01429-w","volume":"17","author":"XY Zhang","year":"2024","unstructured":"Zhang XY, Zhu BC, He M, et al. Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis [J]. J Ovarian Res. 2024;17(1):10.","journal-title":"J Ovarian Res"},{"issue":"11","key":"2041_CR48","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1002\/jcb.29670","volume":"121","author":"CH Dong","year":"2020","unstructured":"Dong CH, Yin FQ, Zhu D, et al. NCALD affects drug resistance and prognosis by acting as a CeRNA of CX3CL1 in ovarian cancer [J]. J Cell Biochem. 2020;121(11):4470\u2013448.","journal-title":"J Cell Biochem"},{"issue":"10","key":"2041_CR49","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41388-024-02940-6","volume":"43","author":"HY Liu","year":"2024","unstructured":"Liu HY, Deng SS, Yao XL, et al. Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer [J]. Oncogene. 2024;43(10):714\u201328.","journal-title":"Oncogene"},{"issue":"12","key":"2041_CR50","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1111\/jog.16077","volume":"50","author":"ML Tian","year":"2024","unstructured":"Tian ML, Li B, Li Y, et al. LncRNA LINC00261 associates with chemoresistance and clinical prognosis in patients with epithelial ovarian cancer [J]. J Obstet Gynaecol Res. 2024;50(12):2271\u20139.","journal-title":"J Obstet Gynaecol Res"},{"key":"2041_CR51","doi-asserted-by":"crossref","unstructured":"Xu R, Peng H, Yang N et al. Nuclear lncRNA CERNA1 enhances the cisplatin-induced cell apoptosis and overcomes chemoresistance via epigenetic activation of BCL2L10 in ovarian cancer [J]. Genes Dis, 20, 10(1): 10\u20131.","DOI":"10.1016\/j.gendis.2021.12.018"},{"issue":"1","key":"2041_CR52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13046-019-1329-2","volume":"38","author":"XR Long","year":"2019","unstructured":"Long XR, Song KQ, Hu H, et al. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis [J]. J Exp Clin Cancer Res. 2019;38(1):345.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"2041_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07278-1","volume":"15","author":"YC Zhong","year":"2024","unstructured":"Zhong YC, Shuai Y, Yang J, et al. LOC730101 improves ovarian cancer drug sensitivity by inhibiting autophagy-mediated DNA damage repair via BECN1. Cell Death Dis. 2024;15(12):89.","journal-title":"Cell Death Dis"},{"key":"2041_CR54","doi-asserted-by":"crossref","unstructured":"Wu AQ, Liu JQ, Zhang XJ et al. Comprehensive network analysis of dysregulated genes revealed MNX1-AS1\/hsa-miR-4697-3p\/HOXB13 axis in ovarian cancer chemotherapy response [J]. Cancer Sci, 20, 113(8): 2627\u201341.","DOI":"10.1111\/cas.15447"},{"issue":"19","key":"2041_CR55","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.7150\/jca.58979","volume":"12","author":"XY Tian","year":"2021","unstructured":"Tian XY, Zuo XH, Hou M, et al. LncRNA-H19 regulates chemoresistance to carboplatin in epithelial ovarian cancer through microRNA-29b-3p and STAT3 [J]. J Cancer. 2021;12(19):5712\u201357.","journal-title":"J Cancer"},{"issue":"4","key":"2041_CR56","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.bbrc.2020.03.087","volume":"526","author":"Q Xu","year":"2020","unstructured":"Xu Q, Lin YB, Li L, et al. LncRNA TLR8-AS1 promotes metastasis and chemoresistance of ovarian cancer through enhancing TLR8 mRNA stability. Biochem Biophys Res Commun. 2020;526(4):857\u201364.","journal-title":"Biochem Biophys Res Commun"},{"key":"2041_CR57","doi-asserted-by":"crossref","unstructured":"Abildgaard C, Do Canto LM, Rainho CA et al. The long non-coding RNA SNHG12 as a mediator of carboplatin resistance in ovarian cancer via epigenetic mechanisms [J]. Cancers (Basel), 20, 14(7): 1664.","DOI":"10.3390\/cancers14071664"},{"key":"2041_CR58","doi-asserted-by":"crossref","unstructured":"Xia XY, Li ZK, Li YJ et al. LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p\/FOXP1 axis [J]. J Gynecol Oncol, 20, 33(6): e81.","DOI":"10.3802\/jgo.2022.33.e81"},{"key":"2041_CR59","doi-asserted-by":"crossref","unstructured":"Ren L, Qing X, Wei J et al. The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer [J]. Cell Death Dis, 20, 14(8): 568.","DOI":"10.1038\/s41419-023-06084-5"},{"issue":"2","key":"2041_CR60","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3892\/ol.2015.3983","volume":"11","author":"DI Wu","year":"2016","unstructured":"Wu DI, Wang TZ, Ren CC, et al. Downregulation of BC200 in ovarian cancer contributes to cancer cell proliferation and chemoresistance to carboplatin [J]. Oncol Lett. 2016;11(2):1189\u201394.","journal-title":"Oncol Lett"},{"issue":"2","key":"2041_CR61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jb\/mvaa036","volume":"168","author":"H Zhao","year":"2020","unstructured":"Zhao H, Wang AX, Zhang ZW. LncRNA SDHAP1 confers paclitaxel resistance of ovarian cancer by regulating EIF4G2 expression via miR-4465. J Biochem. 2020;168(2):171\u201381.","journal-title":"J Biochem"},{"issue":"2","key":"2041_CR62","first-page":"202","volume":"36","author":"YZ Zhao","year":"2021","unstructured":"Zhao YZ, Hong L. lncRNA-PRLB confers paclitaxel resistance of ovarian cancer cells by regulating RSF1\/NF-\u03baB signaling pathway. Cancer Biother Radiopharm. 2021;36(2):202\u201310.","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"2041_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12885-024-12969-1","volume":"24","author":"T Shuang","year":"2024","unstructured":"Shuang T, Wu SY, Zhao YF, et al. The up-regulation of PAK2 indicates unfavorable prognosis in patients with serous epithelial ovarian cancer and contributes to paclitaxel resistance in ovarian cancer cells. BMC Cancer. 2024;24(1):121.","journal-title":"BMC Cancer"},{"issue":"1","key":"2041_CR64","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1515\/biol-2021-0058","volume":"16","author":"B Huang","year":"2021","unstructured":"Huang B, Wei M, Hong L. Long noncoding RNA HULC contributes to paclitaxel resistance in ovarian cancer via miR-137\/ITGB8 axis. Open Life Sci. 2021;16(1):667\u201381.","journal-title":"Open Life Sci"},{"key":"2041_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109711","volume":"123","author":"HL Lin","year":"2020","unstructured":"Lin HL, Shen LE, Lin Q, et al. SNHG5 enhances Paclitaxel sensitivity of ovarian cancer cells through sponging miR-23a. Biomed Pharmacother. 2020;123:109711.","journal-title":"Biomed Pharmacother"},{"key":"2041_CR66","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.2147\/OTT.S147586","volume":"10","author":"JH An","year":"2017","unstructured":"An JH, Lv WL, Zhang YZ. LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther. 2017;10:5377\u201390.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"2041_CR67","first-page":"316","volume":"34","author":"M Zhang","year":"2019","unstructured":"Zhang M, Liu SY, Fu CY, et al. LncRNA KB-1471A8.2 overexpression suppresses cell proliferation and migration and antagonizes the paclitaxel resistance of ovarian cancer cells [J]. Cancer Biother Radiopharm. 2019;34(5):316\u201324.","journal-title":"Cancer Biother Radiopharm"},{"key":"2041_CR68","doi-asserted-by":"crossref","unstructured":"Liu SY, Chen XY, Huang K et al. Long noncoding RNA RFPL1S-202 inhibits ovarian cancer progression by downregulating the IFN-\u03b2\/STAT1 signaling [J]. Exp Cell Res, 20, 422(2): 113438.","DOI":"10.1016\/j.yexcr.2022.113438"},{"key":"2041_CR69","doi-asserted-by":"crossref","unstructured":"Xie YL, Wang LM, Luo Y et al. LINC02489 with m6a modification increase paclitaxel sensitivity by inhibiting migration and invasion of ovarian cancer cells [J]. Biotechnol Genet Eng Rev, 20, 39(2): 1128\u2013114.","DOI":"10.1080\/02648725.2023.2167772"},{"key":"2041_CR70","doi-asserted-by":"crossref","unstructured":"Wu X, Qiu L, Feng H et al. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG\/CLDN6 signaling in epithelial ovarian cancer [J]. Life Sci, 20, 293: 120328.","DOI":"10.1016\/j.lfs.2022.120328"},{"key":"2041_CR71","doi-asserted-by":"crossref","unstructured":"Huang K, Chen XY, Geng Z et al. LncRNA SLC25A21-AS1 increases the chemosensitivity and inhibits the progression of ovarian cancer by upregulating the expression of KCNK4 [J]. Funct Integr Genomics, 20, 23(2): 110.","DOI":"10.1007\/s10142-023-01035-x"},{"issue":"4","key":"2041_CR72","doi-asserted-by":"publisher","first-page":"275","DOI":"10.32604\/or.2022.03561","volume":"29","author":"H Wang","year":"2022","unstructured":"Wang H, Zhou Y, Zhang S, et al. PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16\/CEBPB\/GATA3 axis. Oncol Res. 2022;29(4):275\u201389.","journal-title":"Oncol Res"},{"key":"2041_CR73","doi-asserted-by":"crossref","unstructured":"Tabury K, Monavarian M, Listik E et al. PVT1 is a stress-responsive lncRNA that drives ovarian cancer metastasis and chemoresistance [J]. Life Sci Alliance, 20, 5(11): e202201370.","DOI":"10.26508\/lsa.202201370"},{"key":"2041_CR74","unstructured":"Zhao MW, Lin CJ, Qiu JP. LINC00707 promotes multidrug resistance of ovarian cancer cells by targeting the miR-382-5p\/LRRK2 axis [J]. Acta Biochim Pol, 20, 70(4): 799\u2013806."},{"key":"2041_CR75","doi-asserted-by":"crossref","unstructured":"Coan M, Haefliger S, Ounzain S, Targeting and engineering long non-coding RNAs for cancer therapy. Nat Rev Genet., Watmuff H, Crawford A, Eusse B, Jones AN et al. Structure-function-guided drug development efforts to target lncRNAs. Trends Pharmacol Sci. 2025;46(8):703\u2013721.","DOI":"10.1016\/j.tips.2025.06.007"},{"issue":"31","key":"2041_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202505963","volume":"12","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu H, Zhu C, et al. Tumor small extracellular vesicle-transmitted LncRNA CATED promotes platinum-resistance in high-grade serous ovarian cancer. Adv Sci. 2025;12(31):e05963.","journal-title":"Adv Sci"},{"issue":"3","key":"2041_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70244","volume":"15","author":"Y Wu","year":"2025","unstructured":"Wu Y, Zeng Y, Wu Y, et al. HIF-1\u03b1-induced long noncoding RNA LINC02776 promotes drug resistance of ovarian cancer by increasing polyADP-ribosylation. Clin Transl Med. 2025;15(3):e70244.","journal-title":"Clin Transl Med"},{"issue":"1","key":"2041_CR78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s41065-025-00540-2","volume":"162","author":"N Du","year":"2025","unstructured":"Du N, Zhang X, He C, et al. miR-423-5p mediates LINC00886 regulation of ovarian cancer aggressiveness and immune evasion via the TLR4\/Myd88\/NF-\u03baB\/PD-L1 pathway. Hereditas. 2025;162(1):184.","journal-title":"Hereditas"},{"issue":"12","key":"2041_CR79","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41419-024-07278-1","volume":"15","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Shuai Y, Yang J, et al. LOC730101 improves ovarian cancer drug sensitivity by inhibiting autophagy-mediated DNA damage repair via BECN1. Cell Death Dis. 2024;15(12):893.","journal-title":"Cell Death Dis"},{"key":"2041_CR80","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.biopha.2016.09.087","volume":"84","author":"A Mahdian-Shakib","year":"2016","unstructured":"Mahdian-Shakib A, Dorostkar R, Tat M, et al. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer. Biomed Pharmacother. 2016;84:592\u2013600.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2041_CR81","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41592-022-01626-9","volume":"19","author":"LL Chen","year":"2022","unstructured":"Chen LL. Towards higher-resolution and in vivo understanding of lncRNA biogenesis and function. Nat Methods. 2022;19(10):1152\u20135.","journal-title":"Nat Methods"},{"issue":"2","key":"2041_CR82","first-page":"166","volume":"30","author":"P Ramalingam","year":"2016","unstructured":"Ramalingam P. Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer. Oncology (Williston Park). 2016;30(2):166\u201376.","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"2041_CR83","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415\u201328.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2041_CR84","first-page":"1","volume":"9","author":"DONG Shanshan","year":"2019","unstructured":"Shanshan DONG, Ranran WANG, Ying LONG, et al. Research Progress of Long Non-coding RNA in Epithelial-mesenchymal Transition of Ovarian Cancer [J]. Anti-Tumor Pharm. 2019;9(1):1\u20135.","journal-title":"Anti-Tumor Pharm"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02041-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02041-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02041-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:04:44Z","timestamp":1775037884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02041-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2041"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02041-w","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The corresponding author has received consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}